Application of Topical/Subconjunctival Bevacizumab and Topical Fluorometholone Acetate in Alkali Burn-induced Model of Corneal Angiogenesis

Basit Öğe Kaydı
dc.contributor.authorDursun, Ayhan
dc.contributor.authorArici, Mustafa Kemal
dc.contributor.authorOzec, Ayse Vural
dc.contributor.authorDursun, Feyza
dc.contributor.authorToker, Mustafa Ilker
dc.contributor.authorTopalkara, Aysen
dc.date.accessioned2024-10-26T18:03:35Z
dc.date.available2024-10-26T18:03:35Z
dc.date.issued2010
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractPurpose: To investigate the effect of bevacizumab on corneal neovascularization in an alkali burn -induced model of corneal angiogenesis. Material and Method: Twenty-four Wistar albino rats were used in our study. After chemical cauterization of the cornea, the rats were divided randomly into four groups. Group 1 (control group) received artificial tears twice a day, group 2 received topical fluorometholone acetate twice a day, in group 3, a single dose of bevacizumab (2.5 mg) was administered by a subconjunctival injection, and group 4 received topical bevacizumab 5mg/ml twice a day. Three weeks later, the rat corneas were evaluated by slit-lamp biomicroscopy and corneal photographs were taken with a digital camera, followed by sacrifice of the subjects. The proportional area of vascularized cornea, length of the longest neovascular sprout, corneal oedema and corneal opacity score were assessed. Result: The analysis of digital photographs showed less corneal neovascularization, corneal oedema, corneal opacity score and shorter length of the longest neovascular sprout in the three drug groups than in the control one (p<0.05). The area of corneal neovascularization in groups 3 and 4 was less than in group 2 (p=0.035 and p=0.027, respectively). Corneal neovascularization, corneal oedema and corneal opacity did not differ significantly between the subconjunctival and topical bevacizumab groups. However, statistically significant decrease was observed in the length of the longest neovascular sprout in the topical bevacizumab group (p=0.029). Discussion: Subconjunctival/topical bevacizumab treatment is an effective method in reducing corneal neovascularization. However, we observed that topical bevadzumab is more efficient than subconjunctival bevacizumab and fluorometholone acetate in preventing corneal neovascularization.
dc.identifier.doi10.4274/tjo.40.31
dc.identifier.endpage322
dc.identifier.issn1300-0659
dc.identifier.issn2147-2661
dc.identifier.issue6
dc.identifier.startpage318
dc.identifier.urihttps://doi.org/10.4274/tjo.40.31
dc.identifier.urihttps://hdl.handle.net/20.500.12418/28454
dc.identifier.volume40
dc.identifier.wosWOS:000219188400003
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.language.isotr
dc.publisherTurkish Ophthalmological Soc
dc.relation.ispartofTurk Oftalmoloji Dergisi-Turkish Journal of Ophthalmology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectCorneal neovascularization
dc.subjectbevadzumab
dc.subjectvascular endothelial growth factor (VEGF)
dc.subjectfluorometholone acetate
dc.titleApplication of Topical/Subconjunctival Bevacizumab and Topical Fluorometholone Acetate in Alkali Burn-induced Model of Corneal Angiogenesis
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu